The global hemostasis testing systems market share is estimated to clock a revenue of US$ 3,666 million by 2033. Our healthcare industry experts opine that hemostasis testing systems providers can expect a CAGR of 5.5% through 2033, with a present valuation of US$ 2,149.3 million in 2023.
Key Market Highlights
| Attributes | Details |
|---|---|
| Hemostasis Testing Systems Market Size, 2023 | US$ 2,149.3 million |
| Hemostasis Testing Systems Market Size, 2033 | US$ 3,666 million |
| Value CAGR (2023 to 2033) | 5.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The hemostasis testing systems industry displayed market growth of 3.5% CAGR in the historical period. Over the projected period, the market is anticipated to expand at a CAGR of 5.5% CAGR, driven by the increasing efficiencies in the hemostasis testing systems.
| Attributes | Details |
|---|---|
| Hemostasis Testing Systems Market Size (2018) | US$ 1,792.21 million |
| Hemostasis Testing Systems Market Size (2022) | US$ 2,059.6 million |
| Hemostasis Testing Systems Market (CAGR 2018 to 2022) | 3.5% |
Prominent factors that are pushing the market growth include:
Over the forecast period, the market is projected to be driven by:
The market for wound healing dates back to time immemorial. There is a dedicated market for all, from traditional wound management to sophisticated wound management products. The surging cases of surgical and chronic wounds drive the demand in the traditional wound management market.
Other devoted markets include the hemostasis testing systems market, hemostasis products market, and hemostats for wound closure market. Sales of hemostats for wound closure are expected to close at US$ 5.37 billion by 2033.
In the following table, the hemostasis testing systems market has been compared alongside the hemostasis products market and molecular diagnostics market. The table sheds light on the key drivers, trends, and opportunities that are affecting the respective markets.
As per the analysis, the molecular diagnostics market is expected to expand at a greater CAGR of 18% through 2033. The molecular diagnostics market is predicted to record a total revenue of US$ 17,466.54 million in 2023, which is higher than the other two markets.
Hemostasis Testing Systems Market:
| Attributes | Hemostasis Testing Systems Market |
|---|---|
| CAGR (2023 to 2033) | 5.5% |
| Market Value (2023) | US$ 2,149.3 million |
| Growth Factors |
|
| Future Opportunities | Surging acquaintance with hemostasis conditions is expected to enhance diagnostic rates in the upcoming years. |
| Market Trends | Increasing developments of distinct and industry-first hemostasis testing solutions |
Hemostasis Products Market:
| Attributes | Hemostasis Products Market |
|---|---|
| CAGR (2023 to 2033) | 5.3% |
| Market Value (2023) | US$ 1.58 billion |
| Growth Factors |
|
| Future Opportunities | Surging investments in the healthcare sector by government bodies |
| Market Trends | Lifestyle changes resulting in CVDs |
Molecular Diagnostics Market:
| Attributes | Molecular Diagnostics Market |
|---|---|
| CAGR (2023 to 2033) | 18% |
| Market Value (2023) | US$ 17,466.54 million |
| Growth Factors |
|
| Future Opportunities | Surging adoption of molecular diagnostics in emerging markets |
| Market Trends | Increasing advancements in the research and development of healthcare infrastructure |
Principal Consultant
| Country/ Region | Value Share (2022) |
|---|---|
| North America | 36.8% |
| Europe | 23.5% |
| The United States | 27.2% |
| Germany | 3.6% |
| Japan | 3.4% |
As per the latest estimates, the North America is estimated to attain a market value of around 36.8% in 2023. The United States hemostasis testing systems market for hemostasis testing systems is expected to have a reigning share in the region and the world over. FMI analysts have estimated that the United States is projected to acquire about 27.2% in 2023. The high presence of industry giants in the country is contributing to the market’s growth.
Key players are providing a wide-ranging hemostasis testing portfolio with innovative applications and several industry firsts. Leading manufacturers in the industry are focusing on delivering advanced hemostasis solutions that function well for any lab. From the healthcare point of view, these new solutions, like coagulation analyzers and assays, improve operational efficiency and facilitate better care when combined with lab automation solutions and an IT portfolio.
The market is further ascending on account of increasing partnerships in the country. Sysmex Corporation and Siemens Healthineers, who had entered an agreement for the supply of hemostasis instruments and reagents, is a good case in point.
The European market for hemostasis testing systems is expected to gain about 23.5% in 2023. The German market is projected to have a prominent occupancy in the regional market. FMI analysts have calculated that Germany shares 3.6% of the global share. Apart from this, the United Kingdom is projected to have forecast growth of 4.8% through 2033.
New hemostasis testing systems are being launched to meet the challenging demands of hospitals, academic institutes, and diagnostic laboratories. For instance, Perosphere Technologies is involved in the advanced development and commercialization of a unique POC coagulometer called Perosphere Technologies POC Coagulometer. The device provides prompt and accurate assessment of clotting times throughout different types of anticoagulant medications such as DOACs. The product requires a mere 14 microliters of fresh whole blood and results in easy-to-interpret results with lab-like precision in 3-8 minutes.
Other constituents for market growth include increasing efforts to strengthen the healthcare infrastructure in Europe, increasing patient pool, and surging adoption of advanced automated analyzers. Apart from this, the widespread prevalence of clot disorders is fueling the adoption of hemostasis diagnosis tools.
The Asian countries are expanding at comparatively higher CAGRs. For instance, China is assessed to expand at a CAGR of 6.2%, and India is forecast to expand at a CAGR of 5% through 2033. The market performance is affected by surging income levels in these countries, directly impacting healthcare expenditures in emerging economies.
Asian inhabitants are demonstrating lifestyle-related changes, which have increased dietary-associated disorders. Apart from this, there has been an amplification of research initiatives in the biopharmaceutical sector, which has attracted additional funds to be allocated. The market is expected to be furthered by government initiatives to establish healthcare infrastructure and the movement of pharmaceutical companies into developing nations.
The Asia Pacific market is driven by new business opportunities for hemostasis testing systems providers due to increasing medical issues in the densely populated region. Hemostasis testing is becoming more standardized, thus presenting more opportunities for quality control products and services in the region.
As per the latest estimates by FMI, the hemostasis testing systems market in Japan is projected to account for around 3.4% value share in 2023. The soaring pipeline products for hemostasis in Japan are projected to have a positive influence on the forecast growth. The increasing availability of hemostasis diagnostic devices, including devices deployed for at-home monitoring and in physician’s offices, is augmenting the market growth.
Japan's government has established a comprehensive fee system, which includes a per-diem payment system and diagnosis procedure combination for the acute care hospital reform. This reform aims to lower the care costs to make medical facilities accessible. This development has led to increased competition in the regional healthcare market and a better quality of medical care via an early discharge and separation of medical functions.
The increasing elderly population in the Japan demographics is also contributing to the increased uptake of hemostasis testing systems. The aging rate in Japan has been estimated at 28.4% in 2019, with 90,526 people aged 100 years or over in 2022. Increasing surgical procedures in elders are catalyzing the use of hemostasis testing systems.
Australia's hemostasis testing systems market is emerging as a promising market for leading manufacturers. Market analysts at FMI have tracked that the market is expanding at a CAGR of 3.4% through 2033. The increasing patient awareness regarding hemostasis catalyzes product sales. Increasing investments in the healthcare setup and surging disposable incomes in the country are boosting the segment's growth.
The increasing technological advancements in hemostasis testing equipment are also uplifting the market. Increasing bleeding cases in the country caused by road accidents and other factors are fueling the market growth.
The hemophilia application segment is projected to attain a market share of around 48.3% in 2023, per the recent market predictions by FMI analysts. Surging advancements in clinical trials and pharmaceuticals and increasing treatment options for chronic disorders are expected to fuel the development of the pharmaceutical market across the globe.
| Top Segment | Hemophilia |
|---|---|
| CAGR (2023) | 48.3% |
The Centers for Disease Control and Prevention has successfully developed, executed, and maintained a hemophilia surveillance system. As life expectancy increases, so does the susceptibility of hemophilia patients to be affected by heart disease and various other diseases. New programs are managing hemophilia-associated health problems, thus boosting the consumption of hemostasis testing instruments.
The diagnostic laboratories segment is expected to garner market share of about 59.6% in 2023. The market is expected to attract significant investments from the private as well as public sectors, thus boosting its growth.
| Top Segment | Diagnostic Laboratories |
|---|---|
| CAGR (2023) | 59.6% |
The demand for these systems is projected to be propelled by the constant developments in research and development directed at professional diagnostic tests and the miniaturization of molecular diagnostics. Apart from this, medical device manufacturers are anticipated to profit from the presence of cost-effective and high-quality medical devices.
The growing popularity of diagnostic tests conducted at the point of care among clinicians and patients is fueling the revenues of diagnostic laboratories. Additionally, minimally skilled lab professionals can effectively utilize these devices at labs, contributing to market development.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key players are investing in technological leadership for better diagnostic information and science tools to make a difference in people’s lives. Top companies are exploring new opportunities emerging in the life science field. Another strategy to gain higher market share is to make efforts in the research and development activities to develop high-value-added testing and diagnostic technologies that are inventive, original, and optimize individual health.
Key firms can leverage cutting-edge gene, cell, and protein analysis technologies. In tandem with this, players can be seen constantly developing their service and product portfolio with AI-backed applications and digital offerings. Companies are providing diverse services and solutions to improve the healthcare providers' capacity to offer high-quality, effective care to patients.
New Developments in the Hemostasis Testing Systems Market
The market is expected to generate a revenue of US$ 2,149.3 million in 2023.
The market is expected to expand at a CAGR of 5.5% through 2033.
The United States is projected to grab a maximum market share.
Hemophilia is predicted to generate significant revenue for the market.
Grifols, S.A., BioMarin Pharmaceutical, Inc., and Sanofi are the key competitors in the market.
1. Executive Summary 1.1. Global Market Outlook 1.2 . Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application Type, 2023 to 2033 5.3.1. Hemophilia 5.3.2. Von Willerbrand Disease 5.3.3. Acquired Bleeding Disease 5.4. Y-o-Y Growth Trend Analysis By Application Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Application Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End Use Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End Use Type, 2023 to 2033 6.3.1. in Hospitals 6.3.2. in Academic Institutions 6.3.3. Diagnostics Laboratories 6.4. Y-o-Y Growth Trend Analysis By End Use Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End Use Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The USA 8.2.1.2. Canada 8.2.2. By Application Type 8.2.3. By End Use Type 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Application Type 8.3.3. By End Use Type 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Application Type 9.2.3. By End Use Type 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Application Type 9.3.3. By End Use Type 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Application Type 10.2.3. By End Use Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Application Type 10.3.3. By End Use Type 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Application Type 11.2.3. By End Use Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Application Type 11.3.3. By End Use Type 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Application Type 12.2.3. By End Use Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Application Type 12.3.3. By End Use Type 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Application Type 13.2.3. By End Use Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Application Type 13.3.3. By End Use Type 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Application Type 14.2.3. By End Use Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Application Type 14.3.3. By End Use Type 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Application Type 15.1.2.2. By End Use Type 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Application Type 15.2.2.2. By End Use Type 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Application Type 15.3.2.2. By End Use Type 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Application Type 15.4.2.2. By End Use Type 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Application Type 15.5.2.2. By End Use Type 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Application Type 15.6.2.2. By End Use Type 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Application Type 15.7.2.2. By End Use Type 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Application Type 15.8.2.2. By End Use Type 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Application Type 15.9.2.2. By End Use Type 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Application Type 15.10.2.2. By End Use Type 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Application Type 15.11.2.2. By End Use Type 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Application Type 15.12.2.2. By End Use Type 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Application Type 15.13.2.2. By End Use Type 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Application Type 15.14.2.2. By End Use Type 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Application Type 15.15.2.2. By End Use Type 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Application Type 15.16.2.2. By End Use Type 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Application Type 15.17.2.2. By End Use Type 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Application Type 15.18.2.2. By End Use Type 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Application Type 15.19.2.2. By End Use Type 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Application Type 15.20.2.2. By End Use Type 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Application Type 15.21.2.2. By End Use Type 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Application Type 15.22.2.2. By End Use Type 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Application Type 15.23.2.2. By End Use Type 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Application Type 16.3.3. By End Use Type 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Werfen 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Medtronic 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Siemens Healthcare GmbH 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Haemonetics Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Roche Diagnostics Limited 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Sysmex 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Abbott Laboratories 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Nihon Kohden Corporation 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Beckman Coulter, Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Grifols, S.A. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. BioMarin Pharmaceutical, Inc. 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Sanofi 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. GeTein BioMedical 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Hemostasis Testing Systems Market
